Byron KwanIntegrin-targeted Cancer Immunotherapy

Integrin-targeted cancer therapies have consistently underperformed in clinical trials, despite the fact that upregulation of integrins on tumors in patients have correlated with poor prognosis. In this project, we explore the possibilities of targeting integrins as a tumor antigen for the purpose of recruiting anti-cancer immune responses.